Thirty years of prostate screening data show the benefit keeps growing over time

European Association of Urology

Does prostate cancer screening save lives? After 30 years of data from the longest-running screening trial in Europe, the answer is unambiguously yes. But the harder question has always been whether the benefits justify the costs: unnecessary biopsies, overdiagnosis of slow-growing cancers, and the anxiety that comes with each step of the diagnostic pathway.

Research presented at the European Association of Urology Congress (EAU26) in London, March 13-16, 2026, addresses both sides of that equation, confirming the mortality benefit of screening while demonstrating new strategies to reduce its harms.

One death averted per six men diagnosed

The Gothenburg 1 study, which began in 1994, enrolled 20,000 men aged 50-64. Half were invited for PSA testing every two years until age 70; the other half were not. Jonas Hugosson of the University of Gothenburg now reports the 30-year results: screening averted one prostate cancer death for every 161 men invited to screening, and one death for every six men diagnosed. At 15 years, those ratios were less favorable: one per 311 invited and one per 13 diagnosed.

The take-home message: the mortality benefit of screening grows substantially over time. But so does the problem of overdiagnosis. The screening group had a higher incidence of prostate cancer than expected, meaning some men were treated for cancers that would never have threatened their lives. Hugosson noted that modern diagnostic pathways using MRI and risk stratification did not exist when the study began, and could substantially reduce overdiagnosis today.

PRISM: an international consensus on screening MRI

MRI has become central to prostate cancer diagnosis, but there is no standardized protocol for how it should be used in population-level screening. An international panel of 21 experts, including urologists, radiologists, and pathologists, has now produced the PRISM recommendations: over 300 consensus statements covering when and how to use MRI in screening, how to interpret results, when to biopsy, and when to schedule follow-up scans.

Nikhil Mayor of Imperial College London, who presented the research, noted that the recommendations will be applied in the TRANSFORM trial, which plans to use 10-minute, non-contrast "Prostagram" MRI scans to screen up to 300,000 men. Standardizing MRI protocols across screening programs is essential if screening is to be scaled up without drowning imaging services in demand.

Cutting MRI referrals by 40 to 67 percent

Two separate studies demonstrated strategies to reduce unnecessary MRI referrals. The PRAISE-U study, running across five European sites, found that adding risk stratification tools to PSA screening reduced MRI referrals by 40 to 60 percent compared to PSA alone. Centres using the Rotterdam Prostate Cancer Risk Calculator with transrectal ultrasound saw the greatest reduction.

A Swedish trial testing the Stockholm3 blood test, which combines protein and genetic biomarkers with clinical data, found that performing Stockholm3 before MRI in men with elevated PSA led to 67% fewer MRI scans and 40% fewer biopsies, while still detecting significant cancers. The test helps distinguish men who genuinely need imaging from those whose elevated PSA reflects benign conditions.

Both approaches address a practical bottleneck: population-based screening could send millions of men for MRI scans that most do not need, overwhelming imaging capacity and subjecting men to unnecessary procedures. Risk stratification preserves the benefits of screening while making it feasible to implement at scale.

Low psychological harm from modern screening

One concern about screening is the anxiety it generates. A study within the Goteborg-2 trial surveyed 692 men with elevated PSA about their psychological state during the screening process. While 26% reported feeling worried before biopsy and 9.7% reported distress, only 3.8 to 4.8 percent experienced moderate to severe anxiety, and just 4.2% said worry affected their daily life.

Linda Svensson of Sahlgrenska University Hospital described the findings as reassuring: severe anxiety from modern screening programs is rare, even during the most stressful phase of the diagnostic process.

Conference abstracts, not peer-reviewed trials

Most of these results were presented as conference abstracts at EAU26, not as full peer-reviewed publications. Abstract data are preliminary and may change when complete analyses are published. The Gothenburg 1 study has the longest track record but reflects a screening protocol that predates modern imaging and risk-stratification tools.

The PRAISE-U and Stockholm3 results come from early implementation phases with limited follow-up. Whether risk stratification reduces overdiagnosis and mortality simultaneously, rather than just reducing MRI volumes, remains to be demonstrated in longer-term outcomes data.

The psychological harm study surveyed men in a single Swedish trial, and cultural attitudes toward screening and cancer anxiety vary considerably between countries.

Still, the collection of evidence points in a consistent direction: screening works, and the tools to make it smarter and less harmful are maturing rapidly.